OKYO Pharma CDO reports initial share, option holdings
OKYO Pharma Ltd Chief Development Officer Gary S. Jacob filed an initial ownership report showing he holds 108,920 shares of common stock directly.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
OKYO Pharma Ltd Chief Development Officer Gary S. Jacob filed an initial ownership report showing he holds 108,920 shares of common stock directly. He also reports multiple option awards over common stock with exercise prices ranging from 1.46 to 2.75 per share and expirations between 2033 and 2035.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | COMMON STOCK | -- | -- | -- |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the OKYO Pharma (OKYO) Form 3 filed by Gary S. Jacob show?
Does the OKYO Pharma (OKYO) Form 3 show any recent insider buying or selling?
What role does Gary S. Jacob hold at OKYO Pharma in this Form 3?
AI-generated analysis. How Rhea-AI works. Not financial advice.
